Università degli Studi di Padova

Padua Research Archive - Institutional Repository

P.L.E.A.T.-Preventing Lymphocele Ensuring Absorption Transperitoneally: A Robotic Technique

Original Citation:

Availability:

This version is available at: 11577/3244015 since: 2017-11-20T09:07:06Z

Publisher:

Elsevier Inc.

Published version:

DOI: 10.1016/j.urology.2017.05.031

Terms of use:

Open Access

This article is made available under terms and conditions applicable to Open Access Guidelines, as described at <http://www.unipd.it/download/file/fid/55401> (Italian only)

(Article begins on next page)

Accepted Manuscript

Title: **P.L.E.A.T. - Preventing Lymphocele Ensuring Absorption Transperitoneally:** a Novel Robotic Technique

Author: Fabrizio Dal Moro, Filiberto Zattoni

PII: S0090-4295(17)30568-X

DOI: <http://dx.doi.org/doi: 10.1016/j.urology.2017.05.031>

Reference: URL 20475

To appear in: *Urology*

Received date: 31-3-2017

Accepted date: 19-5-2017

Please cite this article as: Fabrizio Dal Moro, Filiberto Zattoni, **P.L.E.A.T. - Preventing Lymphocele Ensuring Absorption Transperitoneally:** a Novel Robotic Technique, *Urology* (2017), <http://dx.doi.org/doi: 10.1016/j.urology.2017.05.031>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

P.L.E.A.T. - Preventing Lymphocele Ensuring Absorption Transperitoneally:
a novel robotic technique

Authors:

Fabrizio Dal Moro, Filiberto Zattoni

Institutional Affiliation:

Department of Surgery, Oncology and Gastroenterology - Urology

University of Padova

Via Giustiniani 2

35128 Padova - Italy

T: +390498212720 - F: +390498218757

Contact Information (Corresponding Author):

Fabrizio Dal Moro, MD, FEBU

Assistant Professor

Department of Surgery, Oncology and Gastroenterology - Urology

University of Padova

Via Giustiniani 2

35128 Padova - Italy

T: +390498212720 - F: +390498218757

E: fabrizio.dalmoro@unipd.it

Word Count of Abstract: 137

Word Count of Text: 1561

Keywords: Robot-Assisted Radical Prostatectomy; Pelvic Lymph Node Dissection;
Lymphocele

Declaration of interest

'Conflicts of interest: none'

Acknowledgment

Support/Financial Disclosures: None

Abstract

Objectives

To reduce the risk of symptomatic lymphocele after robotic pelvic lymph node dissection (PLND), we present a novel technique (P.L.E.A.T.): the peritoneum is 'pleated' along its midline, leaving two lateral openings and allowing lymphatic fluid to drain away from the pelvis and into the abdomen.

Methods

We analysed a single-surgeon series of PLNDs during Robotic Radical Prostatectomy, comparing 195 'standard' PLNDs (in which the peritoneum was 're-approximated' or left completely open) with 176 cases in which P.L.E.A.T. was performed.

Results

In the group without P.L.E.A.T., 8 cases of symptomatic (Grade ≥ 3 , according to the Clavien Dindo Classification) lymphoceles (4.1%) were recorded. Only one P.L.E.A.T. patient complained of symptoms due to a lymphocele ($p=0.039$). No patient reported complications due to the procedure.

Conclusions

The P.L.E.A.T. technique is a fast, easy-to-perform and safe method of reducing the risk of symptomatic lymphocele after transperitoneal robotic PLND.

Introduction

The formation of a pelvic lymphocele is a complication which may follow robotic pelvic lymph node dissection (PLND). Most cases of lymphocele are asymptomatic (incidence reaches 30%) and are often an incidental finding during follow-up^{1,2}. When symptoms do occur (incidence after robotic PLND 0-8% - Grade ≥ 3 , according to the Clavien Dindo Classification³), they are typically related to compression of surrounding structures (pelvic pain, leg edema, deep vein thrombosis)⁴.

An injury to the lymphatic vessels is the main causative factor in the formation of a lymphocele. Potential risk factors for its development are: surgical approach (laparotomy vs. laparoscopy/robotic), number of lymph nodes removed, lymph node status, and type of cancer.

Several studies have shown a lower incidence of lymphocele after robotic radical prostatectomy (RARP) with PLND, by means of a transperitoneal approach rather than traditional open or extraperitoneal approaches. Initial peritoneotomy is probably the main reason for the decreased incidence of lymphocele formation during transperitoneal PLND. The opening created during this approach allows lymphatic fluid to drain away from the pelvis and into the abdomen. Nevertheless, the incidence of lymphocele is also higher than anticipated, in view of the believed protective effect of the transperitoneal approach^{5,6}.

The aim of this study was to analyse the incidence to date of symptomatic lymphocele and to assess the protective role of a novel surgical technique to prevent its formation in a

86 large cohort of patients followed after robotic PLND and transperitoneal RARP for prostate
87 cancer.

88 **Materials and Methods**

89 We analysed a single-surgeon (FDM) series of PLNDs during RARP, comparing 195
90 'standard' PLNDs (in which the peritoneum was 're-approximated' or left completely open)
91 with 176 cases, in which a 'partial' closure of the peritoneum was performed.

92 The aim of this novel technique, named P.L.E.A.T. (acronym: Preventing Lymphocele
93 Ensuring Absorption Transperitoneally) is to create a pathway lined by peritoneum, to
94 direct lymphatic fluid out of the pelvis and into the peritoneal cavity where it can be
95 absorbed: the peritoneum is 'pleated' along its midline and fixed to the fibers of the *rectus*
96 *abdominis* muscles, near the pubis. The P.L.E.A.T. technique, leaving two lateral
97 openings, allows lymphatic fluid to drain away from the pelvis and into the abdomen
98 [Figure #1].

99
100 We excluded the first 50 cases of PLND performed by the surgeon FDM from this series:
101 in these cases we found 4 symptomatic lymphoceles, but because the cooperation with
102 other surgeons and a non-standardized technique, we decided to exclude the above cases
103 in order to avoid any bias due to the initial learning curve. Although including the first 50
104 cases would have allowed us to increase the level of significance of this study (p value
105 from 0.038 to 0.01), it would not have been methodologically correct.

106 All patients were managed similarly in the perioperative period (i.e. same timing for
107 catheter/pelvic drain removal). In view of Deep Vein Thrombosis (DVT) prophylaxis, we
108 treated all patients with subcutaneous low molecular weight heparin (Enoxaparin) at a
109 dosage of 3000 UI/day (modified according to specific risk, renal function, body mass
110 index) and graduated compression stockings. We usually continued Enoxaparin
111 administration for one month after surgery.

112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137

We considered as ‘symptomatic’ any patient who presented with pelvic symptoms such as pelvic fullness, fever, or lower abdominal pain, even if slight, with ultrasound/CT/MRI feedback showing a lymphocele, according to Kim’s criteria⁷.

Patients who developed DVT complained of pain, swelling, or discoloration of the affected extremity; diagnosis was confirmed with doppler/compression ultrasonography.

Statistical analysis was performed with application of Fisher’s, Mann-Whitney and Pearson’s Chi-Square Tests.

Results

The demographic and clinical characteristics of patients in both groups were comparable, as was lymph nodes status ($p>0.05$). There were statistically significant differences in the pathological staging of cancers ($p<0.05$), and the median number of lymph nodes removed (5 vs 10 in standard and P.L.E.A.T. groups, respectively; $p<0.00001$) [see Table #1].

The cases of extended PLND (25 vs 35, in standard and P.L.E.A.T. groups, respectively) were not statistically different ($p=0.064$). In the 195 PLNDs without P.L.E.A.T. reconstruction, we found symptomatic lymphocele (Grade ≥ 3 , according to the Clavien Dindo Classification³) in 8 cases (4.1%) distributed homogeneously (and not grouped in the first cases). Only one P.L.E.A.T. patient complained of symptoms due to a bilateral lymphocele, which required percutaneous drainage ($p=0.039$). Specific data concerning these patients and the management of complications are shown in Table #2. No patient reported either complications related to the procedure or any kind of abdominal/pelvic discomfort.

138

139 **Comment**

140 The problem of preventing lymphocele after PLND remains an interesting challenge,
141 particularly in cases of extended PLND. Various solutions have been proposed to limit the
142 risk, such as the use of new energy sources, or collagen patches coated with human
143 coagulation factors which provide rapid and reliable hemostasis by creating a robust fibrin
144 clot adhering to the tissue surface^{8,9}.

145

146 Considering exclusively surgical techniques, a 'peritoneal fenestration' is proposed to
147 prevent the above-mentioned complications: this concept has been extensively studied to
148 prevent lymphocele development in renal transplantation and a recent review confirmed its
149 effectiveness¹⁰.

150 In fact, during open radical prostatectomy or extraperitoneal RARP, the occurrence of
151 lymphocele is significantly lower with fenestration, and the formation of symptomatic
152 lymphocele requiring surgical intervention was *de facto* eliminated, without an increase in
153 postoperative morbidity, as documented by Stolzenburg et al.¹¹.

154

155 Nevertheless, although transperitoneal PLND, as opposed to traditional open or
156 extraperitoneal approaches, has shown a lower incidence of lymphocele, it still remains
157 significant¹²: it may be due to spontaneous 're-approximation' of the edges of the
158 peritoneum, incised laterally to the medial obliterate ligaments. In many cases, after
159 release of the pneumoperitoneum after a RARP with PLND, even though the bladder is left
160 'dropped', perivesical fat adheres to the PLND bed, creating a closed space in which
161 lymphatic fluid accumulates. As reported by Lebeis et al., the bladder often forms the
162 medial wall of the lymphocele cavity¹³.

163 In addition, when the peritoneum is 're-approximated', the final result is similar to an
164 extraperitoneal open/laparoscopic radical prostatectomy.

165 Some authors have proposed the insertion of a peritoneal flap, created by dropping the
166 bladder from the abdominal wall and fixing it to the lateral aspect of the bladder, at the end
167 of the procedure: the 'window' prevents scarring to the bladder over the PLND area,
168 allowing lymphatic fluid to drain into the peritoneal cavity and thus be reabsorbed¹³. As
169 reported by the authors, this peritonealization of the lateral aspect of the bladder with a
170 interposed flap is effective in preventing post-operative lymphoceles. However, this
171 technique fixes the bladder inferiorly.

172 As previously reported¹⁴, during RARP we usually perform the CoRPUS reconfiguration, in
173 which, after the creation of a complete support for the urethra, we put a final stitch from the
174 anterior wall of the bladder to the pubis allowing the bladder, bladder neck and/or posterior
175 urethra axis to be properly aligned. With this technique, the solution proposed by Lebeis et
176 al. is not feasible.

177

178 It was from these considerations that we devised and applied the P.L.E.A.T. surgical
179 technique. The unique nature of this strategy is that the two lateral 'openings' do not
180 collapse when the pneumoperitoneum is removed, because pleating the bladder (into a
181 more natural position) means that we pull the peritoneum medially, thereby avoiding any
182 possible spontaneous re-approximation.

183 The results demonstrated the significant protective effect of this technique in preventing
184 symptomatic lymphocele, compared with the widespread standard approach, although the
185 number of lymph nodes removed in the P.L.E.A.T. group was significantly higher
186 ($p<0.00001$).

187 The strengths of this study are: 1. the surgical technique for both limited and extended
188 PLND was standardized (with only one Hem-o-lock[®] clip distal to Cloquet's node and bi-

polar coagulation); 2. In view of the incidence of symptomatic lymphocele reported in the literature, the number of patients enrolled was adequate (powered statistical analysis); 3. the technique is simple and easy-to-perform (2-3 min) and is thus easily replicable; 4. the absence of complications due to the technique allows us to conclude that it is safe.

The limitations of this study are: 1. all the procedures were performed by the same skilled robotic surgeon: although this avoided any bias due to the differing proficiency and/or technique of several surgeons, we realize that it may represent a limitation. In effect, it was in order to reduce the impact of the learning curve that we decided not to consider the first 50 cases; 2. this is a non-randomized study, based on analysis of medical records; 3. both limited and extended PLND were examined in the same analysis, although both techniques were similarly distributed in the two groups, nullifying any bias (25 vs 35 extended PLNDs in the standard and P.L.E.A.T. groups, respectively; $p>0.05$). Although not significantly higher, the number of extended PLNDs performed in the second 'era' far from being a demonstration of an improvement in technique, only demonstrates an increase in the number of indications of more clinically extended neoplasms, as confirmed by the different percentage of pT2/pT3 in the two groups. Considering that both the number of lymph nodes removed and the type of cancer represent well-documented risk factors for symptomatic lymphoceles, this distribution of cases reinforces the protective role of the P.L.E.A.T. technique.

Conclusions

Our preliminary analysis confirms that the P.L.E.A.T. technique is a fast, economic, easy-to-perform and safe method for reducing the risk of symptomatic lymphocele after transperitoneal robotic PLND. Randomized clinical trials (preferably multi-institutional) are

214 needed to confirm the efficacy of P.L.E.A.T., matching other recently reported studies
215 comparing differing techniques for lymphoceles.

216

Accepted Manuscript

References

- [1] Rassweiler JJ, Hruza M, Teber D, Su LM. Laparoscopic and robotic assisted radical prostatectomy—critical analysis of the results. *Eur Urol* 2006;49:612–624.
- [2] Orvieto MA, Coelho RF, Chauhan S, Palmer KJ, Rocco B, Patel VR. Incidence of lymphoceles after robot-assisted pelvic lymph node dissection. *BJU Int.* 2011;108:1185–1190.
- [3] Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205-213.
- [4] Ploussard G, Briganti A, de la Taille A, et al. Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. *Eur Urol* 2014;65:7–16.
- [5] Chung JS, Kim WT, Ham WS, et al. Comparison of oncological results, functional outcomes, and complications for transperitoneal versus extraperitoneal robot-assisted radical prostatectomy: a single surgeon's experience. *J Endourol* 2011;25:787–792.
- [6] Solberg A, Angelsen A, Bergan U, et al. Frequency of lymphoceles after open and laparoscopic pelvic lymph node dissection in patients with prostate cancer. *Scand J Urol Nephrol* 2003;37:218–221.
- [7] Kim JK, Jeong YY, Kim YH, et al. Postoperative pelvic lymphocele: treatment with simple percutaneous catheter drainage. *Radiology* 1999;212:390–394.
- [8] Grande P, Di Pierro GB, Mordasini L, et al. Prospective randomized trial comparing titanium clips to bipolar coagulation in sealing lymphatic vessels during pelvic lymph node dissection at the time of robot-assisted radical prostatectomy. *Eur Urol* 2017;71:155–158.

- 241 [9] Marchioni M, Ingrosso M, De Francesco P, Primiceri G, Manco R, Tenaglia RL. The
242 use of haemostatic agents and sealants for the prevention of lymphocele after urological
243 surgery: a review of the literature. *Surg Technol Int* 2015;27:45–50.
- 244 [10] Mihaljevic AL, Heger P, Abbasi Dezfouli S, Golriz M, Mehrabi A. Prophylaxis
245 of lymphocele formation after kidney transplantation via peritoneal fenestration:
246 a systematic review. *Transpl Int* 2017;30:534-555.
- 247 [11] Stolzenburg JU, Wasserscheid J, Rabenalt R, et al. Reduction in incidence of
248 lymphocele following extraperitoneal radical prostatectomy and pelvic lymph node
249 dissection by bilateral peritoneal fenestration. *World J Urol* 2008;26:581–586.
- 250 [12] Zorn KC, Katz MH, Bernstein A, et al. Pelvic lymphadenectomy during robot-assisted
251 radical prostatectomy: Assessing nodal yield, perioperative outcomes, and complications.
252 *Urology* 2009;74:296–302.
- 253 [13] Lebeis C, Canes D, Sorcini A, Moinzadeh A. Novel technique prevents lymphoceles
254 after transperitoneal robotic-assisted pelvic lymph node dissection: peritoneal flap
255 interposition. *Urology* 2015;85:1505-1509.
- 256 [14] Dal Moro F, Crestani A, Valotto C, Zattoni F. CORPUS--novel COmplete
257 Reconstruction of the Posterior Urethral Support after robotic radical prostatectomy:
258 preliminary data of very early continence recovery. *Urology* 2014;83:641-647.
- 259

260 **Legends:**

261

262

263 **Figure #1:** (A) Drawing and (B) Intraoperative photo showing bladder peritoneum 'pleated'
264 along midline, leaving two lateral openings, according to the P.L.E.A.T. technique.

265

266

267

268

Accepted Manuscript

269 Table 1. Comparison of patient characteristics in 'standard' Group and P.L.E.A.T. Group.

	Group 1	Group 2	
	(standard)	(P.L.E.A.T.)	<i>p</i>
Parameter			
<i>Number of Patients</i>	195	176	
<i>Pathological Staging (%)</i>			<i>0.03*</i>
pT0	10 (5.1)	1 (0.6)	
pT2(a-b-c)	110 (56.4)	98 (55.7)	
pT3(a-b)/pT4	75 (38.5)	77 (43.7)	
<i>Lymph Nodes Removed</i>			
Median (IR)	5 (0-11)	10 (6.5-15)	<i><0.00001^{\$}</i>
Positive Nodes (%)	5 (2.6)	11 (6.25)	<i>0.12[#]</i>
<i>Extended PLNDs (%)</i>	25 (12.8)	35 (19.9)	<i>0.068*</i>
<i>Symptomatic Lymphocele (%)</i>	8 (4.1)	1 (0.6)	<i>0.038[#]</i>
<i>Symptomatic Lymphocele in Extended PLNDs (%)</i>	1/25 (4)	1/35 (2.9)	<i>n.s.</i>
<i>Follow-up days (median, IQR)</i>	1951 (1678-2192)	731.5 (508-1033)	
			<i>*Chi-Square</i> <i>^{\$} Mann-Whitney test</i> <i>[#]Fisher's test</i>

270
271

272 Table 2. Patients with symptomatic lymphocele

Case #	Technique	Symptoms	Postop Day #	Management	Successful
2	no PLEAT	fever, DVT	36	PC Drainage	yes
18	no PLEAT	pain	45	PC Drainage	yes
82	no PLEAT	fever	11	PC Drainage	yes
91	no PLEAT	fever, LUTS	38	PC Drainage	yes
98	no PLEAT	fever	145	Antibiotics	yes
120	no PLEAT	fever, gain	26	PC Drainage	yes
177	no PLEAT	fever, DVT	32	PC Drainage	yes
182	no PLEAT	DVT	25	PC Drainage	yes
367	PLEAT	DVT	26	PC Drainage	yes

273 DVT: Deep Venous Thrombosis; LUTS: Low Urinary Tract Symptoms; PC: Percutaneous
 274